Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) will present new data on its next-generation capsid AAV-SLB101 and cardiac gene therapy pipeline at the 22nd Global CardioVascular Clinical Trialists Forum, December 8-10, 2025, in Washington, D.C.

Chief Medical Officer Gabriel Brooks, M.D. will present two talks, a poster on AAV-SLB101 showing potent cardiac tropism and initial clinical safety, and join two panels; Nicolas Christoforou, Ph.D. will present preclinical work on a gene therapy for catecholaminergic polymorphic ventricular tachycardia (CPVT) and join a panel.

Presentations will be posted after the conference on the company’s Scientific Publications & Presentations page.

News Market Reaction – SLDB

-1.04%

1 alert

-1.04% News Effect

On the day this news was published, SLDB declined 1.04%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $5.96 Vol: Volume 1,106,034 is essen...

normal vol

$5.96 Last Close

Volume Volume 1,106,034 is essentially in line with the 20-day average of 1,107,317. normal

Technical Shares at $5.77 trade above the 200-day MA $4.90, but remain 21.71% below the $7.37 52-week high.

Peers on Argus

Sector peers show mixed moves, with names like ALMS up 30.82% and others such as...

1 Up

Sector peers show mixed moves, with names like ALMS up 30.82% and others such as LXRX down 1.41%. Momentum scanners only flag FULC moving up strongly, suggesting today’s setup around SLDB is more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Dec 01 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 01	Inducement equity grants	Neutral	-2.1%	RSU inducement awards to new hires under 2024 Inducement Plan.
Dec 01	Regulatory designation	Positive	-4.0%	FDA Rare Pediatric Disease designation for SGT-212 gene therapy for FA.
Nov 17	Licensing collaboration	Positive	+2.4%	Non-exclusive license for AAV-SLB101 with Andelyn to broaden capsid access.
Nov 11	Investor conferences	Positive	+9.2%	Participation in Jefferies and Piper Sandler healthcare investor conferences.
Nov 06	Regulatory pathway update	Positive	+7.3%	UK ILAP Innovation Passport for SGT-003 and progress of INSPIRE/IMPACT trials.

Pattern Detected

Positive regulatory and partnership updates have more often been followed by aligned positive price reactions, with one notable negative divergence on favorable FDA designation news.

Recent Company History

Over the past month, Solid Biosciences has reported multiple regulatory and clinical milestones. On Nov 6, SGT‑003 received an Innovation Passport under the UK ILAP with Phase 1/2 and Phase 3 trials progressing. A Nov 17 AAV‑SLB101 licensing deal with Andelyn highlighted broad capsid adoption. On Dec 1, SGT‑212 gained FDA Rare Pediatric Disease designation, while routine inducement RSUs were granted the same day. Today’s CVCT Forum presentations extend this communication focus on AAV‑SLB101 and cardiac gene therapy.

Market Pulse Summary

This announcement highlights Solid Biosciences’ intent to showcase AAV‑SLB101 and its cardiac gene t...

Analysis

This announcement highlights Solid Biosciences’ intent to showcase AAV‑SLB101 and its cardiac gene therapy pipeline at the CVCT Forum, emphasizing cardiac tropism and initial clinical safety. It follows recent milestones including UK ILAP recognition for SGT‑003 and FDA Rare Pediatric Disease designation for SGT‑212. Investors may watch for detailed clinical data, evolution of licensing activity around AAV‑SLB101, and any future regulatory or trial updates that build on these scientific communications.

Key Terms

capsid, aav-slb101, gene therapy, catecholaminergic polymorphic ventricular tachycardia, +2 more

6 terms

capsid medical

"data from its next-generation, proprietary capsid AAV-SLB101 and its cardiac"

A capsid is the protein shell that encases a virus’s genetic material, like the hard case around a fragile object. For investors, the capsid matters because its shape and chemistry determine how a virus or viral vector behaves—affecting vaccine effectiveness, gene therapy delivery, immune reactions, manufacturing complexity, and related patents, all of which can influence the commercial prospects and regulatory path of biotech products.

aav-slb101 medical

"next-generation, proprietary capsid AAV-SLB101 and its cardiac gene therapy"

AAV-SLB101 is a coded name for an experimental gene therapy that uses a harmless viral shell (an adeno-associated virus, or AAV) to deliver a corrective gene into patients’ cells. Investors care because such therapies can offer one-time, potentially curative treatments for serious diseases, but they also carry high development, manufacturing and regulatory risks; progress through clinical trials and regulatory milestones typically drives large changes in value.

gene therapy medical

"preclinical development of a gene therapy for catecholaminergic polymorphic"

Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.

catecholaminergic polymorphic ventricular tachycardia medical

"gene therapy for catecholaminergic polymorphic ventricular tachycardia (CPVT) and"

A rare inherited heart rhythm disorder that causes the heart’s electrical system to misfire during physical activity, stress or sudden excitement, producing dangerously fast, irregular beats that can lead to fainting or sudden cardiac arrest. Investors should care because it creates a defined patient population and urgent medical need that can affect demand for drugs, devices, diagnostics, clinical trial design, regulatory review and insurance costs—similar to how a known flaw in a product drives focused repair, replacement and liability markets.

cardiac tropism medical

"Capsid Demonstrates Highly Potent Cardiac Tropism and Initial Clinical Safety"

Cardiac tropism describes a therapy’s or biological agent’s tendency to preferentially reach, enter, or act on heart tissue rather than other parts of the body. For investors, cardiac tropism matters because strong heart-targeting can increase a treatment’s effectiveness for cardiac diseases or raise safety concerns if unintended heart exposure occurs, influencing clinical success, regulatory review, development costs, and market potential—think of it as how well a delivery truck is guided to a specific house.

clinical safety medical

"Capsid Demonstrates Highly Potent Cardiac Tropism and Initial Clinical Safety"

Clinical safety describes the assessment and monitoring of whether a medical treatment, drug, or device causes harmful side effects or risks to patients during human testing and use; think of it as an ongoing safety checklist and watchful guard for people receiving a therapy. It matters to investors because a strong clinical safety profile increases the chance of regulatory approval, reduces the risk of costly delays, recalls, or lawsuits, and helps predict a product’s market acceptance and long-term value.

AI-generated analysis. Not financial advice.

CHARLESTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it will present data from its next-generation, proprietary capsid AAV-SLB101 and its cardiac gene therapy pipeline at the Global CardioVascular Clinical Trialists (CVCT) Forum taking place December 8-10, 2025, in Washington, D.C. Gabriel Brooks, M.D., Solid’s Chief Medical Officer, will exhibit a poster, deliver two presentations and participate in two panel discussions. Dr. Brooks has also been selected as a CVCT faculty member. Additionally, Nicolas Christoforou, Ph.D., Solid’s Head of Discovery and Translational Development, will deliver a presentation on the preclinical development of a gene therapy for catecholaminergic polymorphic ventricular tachycardia (CPVT) and participate in a panel discussion.

The CVCT Forum is an annual, invite-only workshop that aims to cultivate a multi-stakeholder exchange to enhance clinical trials, streamline regulatory approval processes, and facilitate the implementation of trial-based evidence.

“We will present data illustrating the potential of our precision genetic approach to cardiac diseases, with a specific focus on the benefits of our proprietary, rationally designed capsid, AAV-SLB101,” said Dr. Brooks. “We look forward to discussing our findings with the community of scientists and trialists as we come together with the goal of transforming the future of cardiovascular disease treatments.”

Poster:

• Title: AAV-SLB101: A Next-Generation Rationally Designed Capsid Demonstrates Highly Potent Cardiac Tropism and Initial Clinical Safety
  

Presentations:

Gene-Based Cardiac Therapy Part 1
The Basics

• Title: AAV-SLB101: A Next-Generation Rationally Designed Capsid Demonstrates Highly Potent Cardiac Tropism and Initial Clinical Safety
• Presenter: Dr. Gabriel Brooks

Gene-Based Cardiac Therapy Part 2
The Trials and Beyond

• Title: Cardiac Gene Therapy – An Industry Prospective: Drive to Inflection Point
• Presenter: Dr. Gabriel Brooks

• Title: Preclinical Development of a Gene Therapy Strategy for Patients with Catecholaminergic Polymorphic Ventricular Tachycardia
• Presenter: Dr. Nicolas Christoforou on behalf of Silvia Priori, M.D., Ph.D., Professor of Cardiology at the University of Pavia and Director of the Molecular Cardiology Unit at the IRCCS Maugeri in Pavia, Italy

Panel Discussions:

The CVCT Multi-Stakeholder Think Tank Debate
Gene-Based Cardiac Therapy Part 1

• Title: The Basics. What it Needs to Get Gene Therapy Innovations into Clinical Stage?
• Panelist: Dr. Gabriel Brooks

The CVCT Multi-Stakeholder Think Tank Debate
Gene-Based Cardiac Therapy Part 2

• Title: How are We Getting Around Specific Gene Therapy Clinical Trial Challenges?
• Panelists: Drs. Gabriel Brooks and Nicolas Christoforou

Following completion of the conference, presentations will be available on the Scientific Publications & Presentations page of the Our Science section of the Company website, or by clicking here.

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and prospects for the Company; the ability to successfully achieve and execute on the company’s goals, priorities and achieve key clinical milestones; the Company’s pipeline of capsid products, including SLB-101, and programs for neuromuscular and cardiac diseases, including its SGT-003 candidate and other clinical and pre-clinical programs and expectations for clinical development, initiation and enrollment in clinical trials, dosing, availability of clinical trial data and potential accelerated approval;; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “working” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the company’s ability to advance and license AAV-SLB101 and advance SGT-003 and its other clinical and preclinical programs and capsid libraries on the timelines expected or at all; obtain and maintain necessary approvals from the FDA and other regulatory authorities; replicate in clinical trials positive results found in preclinical studies and early-stage clinical trials of the company’s product candidates; obtain, maintain or protect intellectual property rights related to its capsid libraries and product candidates; compete successfully with other companies that are seeking to develop capsids, capsid libraries, Duchenne, Friedreich’s ataxia and other neuromuscular and cardiac treatments and gene therapies;, achieve its other business objectives and continue as a going concern. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof and should not be relied upon as representing the company’s views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so.

Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com

FAQ

When will Solid Biosciences (SLDB) present at the CVCT Forum in 2025?

Solid will present at the CVCT Forum on December 8-10, 2025, in Washington, D.C.

What data will SLDB present about AAV-SLB101 at the December 2025 CVCT Forum?

SLDB will present a poster and talks on AAV-SLB101 highlighting potent cardiac tropism and initial clinical safety.

Who from Solid Biosciences will speak about cardiac gene therapy at CVCT 2025?

Chief Medical Officer Gabriel Brooks, M.D. and Head of Discovery Nicolas Christoforou, Ph.D. will deliver presentations and join panel discussions.

Will Solid Biosciences (SLDB) present preclinical data on CPVT at CVCT 2025?

Yes. Nicolas Christoforou will present preclinical development of a gene therapy strategy for CPVT.

Where can investors find Solid Biosciences' CVCT Forum presentations after the event?

Presentations will be available on the company’s Scientific Publications & Presentations page after the conference.

What topics will SLDB panel discussions cover at the December 2025 CVCT Forum?

Panels will focus on advancing gene therapy to clinical stage and addressing specific gene therapy trial challenges.